Aromasin contains 25mg of exemestane, an irreversible steroidal aromatase inactivator. By inhibiting aromatase, exemestane reduces the conversion of androgens into estrogen, lowering estrogen exposure in the body. �

Pfizer Medical +1

The medicine has established use in postmenopausal women with estrogen-receptor-positive early breast cancer following appropriate prior treatment, as well as in advanced breast cancer following tamoxifen therapy. The supplied pharmaceutical presentation contains 25mg exemestane per tablet. �

Pfizer Medical +1

Because estrogen reduction can affect bone health, joint comfort, and other physiological functions, treatment should be used under appropriate medical supervision. Commonly reported effects include hot flushes, fatigue, arthralgia, headache, and increased sweating.